WallStSmart

Merck & Company Inc (MRK)vsQuantum BioPharma Ltd. (QNTM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

QNTM

Avoid

16

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 1/9Altman Z: -32.12
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Intrinsic value data unavailable for QNTM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

QNTM1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

QNTM4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.83M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : QNTM

The strongest argument for QNTM centers on Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : QNTM

The primary concerns for QNTM are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

QNTM carries more volatility with a beta of 0.46 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (36/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Quantum BioPharma Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. With a robust pipeline of biopharmaceutical products, QNTM is committed to utilizing cutting-edge research and development to address critical unmet medical needs in these therapeutic areas. The company's strategic partnerships and experienced leadership position it to successfully navigate the complexities of the biopharmaceutical landscape. As the demand for groundbreaking therapeutics rises, Quantum BioPharma presents a strong investment opportunity for institutional investors seeking exposure to the dynamic healthcare sector.

Visit Website →

Want to dig deeper into these stocks?